Last mentioned: Feb 26, 2026
Anticipated Filing
Expected regulatory submission for WVE-N531 in Duchenne muscular dystrophy.
FY 2025 Earnings
Wave and Collegium release full-year financial results and 2026 guidance.
RNA Editing Milestone
WVE-006 demonstrates successful RNA editing in AATD patients.
DMD Breakthrough
Wave reports industry-leading dystrophin expression for WVE-N531.
Wave Life Sciences and Collegium Pharmaceutical released their Q4 and full-year 2025 results, highlighting a pivotal year for RNA editing and specialty pain management. Wave's transition toward a commercial-stage biotech is accelerated by its GSK partnership and landmark clinical data in Alpha-1 antitrypsin deficiency.
This page surfaces every story mentioning Wave Life Sciences across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Wave Life Sciences was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |